SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Confirmation Number 9072
Application Number 10/810,755
Filing Date 03/26/2004
First Named Inventor Michael J. Renzi
Group Art Unit 1040
Examiner Name Rttomey Docket Number PRD2052USNP

			U.S. PAT	ENT DOCUM	ENTS			
Evenings	Cite	Name of Patentee or Applicant	U.S	U.S. Patent Document Kind Code ²			Pages, Colum	ns, Lines, where relevant relevant figures appear
Examiner Initials	No.1	of Cited Document	Nun			f known)	passages or	relevant figures appear
	ļ			<u></u> .				
								•
	<u>.</u>							
							_	
		FOI		TENT DOCUM				
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign f	Patent Documen Number ⁴ K	it IndCode ⁵	where re	Columns, Lines, levant passages evant figures appear	T ⁶
No.1			-	1.011001	1		- Provide	
				 				,
			-	-	 			
 			ļ <u>.</u>	 	ļ	ļ		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

International Search Report dated March / 2005, for corresponding international application PCT/US04/09443.

Examiner Signature

Date Considered

MOA & 8 5002 PR

PTO/S8/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid CMB control number.

Stitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

Int J Mol Med. 1998;1:235-241

2002;99:2258-2263

Oncol. 2001;28:66-70.

micronia managementa and incoming and	and a displayer a vote of the control interior.
Confirmation Number	9072
Application Number	10/810,755
Filing Date	03/26/2004
First Named Inventor	Michael J. Renzi
Group Art Unit	1046 1647
Examiner Name	K.M. KRISEMA
Attorney Docket Number	PRD2052USNP

					U.S. PATENT DOCUMENTS	ocket Number	PRDZUJZUJNF	
		U.S. Pa	tent Document			Date of Publication	n Pages, Columns, L	
Exam Initials	Cite No.1	Kind Co Number (if know			Name of Patentae or Applicant of Cited Document	of Cited Documer		iges or
MY		6121246		Α	Isner	09/19/2000		•
M		6165	783	A	Weiss et al	12/26/200	0	
	ļ	<u> </u>						
						<u> </u>		
						·		
			·		FOREIGN PATENT DOCUMENTS			
Exam Initials	Cite	Foreign Patent Document Office ³ Number ⁴ KindCode		ode ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T [©]
		CA	2 353 553	A1	Ehrenreich	06-22-2000		
11	P	wo	00/35475	A2	Ehrenreich	06-22-2000	English Abstract	No
<u>.</u>		<u> </u>		-			······	_
					ART - NON PATENT LITERATURE D			
Exam Initials	Cite No.'	inclu journal	ice name of the auth I, serial, symposium,	or (in CAP catalog, e	ITAL LETTERS), title of the article (when a tc.), date, page(8), volume-issue number(8),	opropriate), title of the it publisher, city and/or (tem (book, magazine, country where published	T²
RY		Exper:	imental Brain	Injury	oietin Crosses The Blood-Br. ", P.N.A.S. U S A (2000) 97	:10526-10531		
H]]		Campa	na WM, et al.	, Ider	tification of a neurotroph	ic sequence in	erythropoietin.	

Examiner Deta Considered 4/3/07

Celik M, et. al., Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A.

Cerami A, et. al., Effects of epoetin alfa on the central nervous system. Semin

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 See attached Kinds of U.S. Patant Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.S). 4 For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document, 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 tf

Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

Diespend & Composition and American and Composition (Composition Composition C											
Confirmation Number	9072										
Application Number	10/810,755										
Filing Date	03/26/2004										
First Named Inventor	Michael J. Renzi										
Group Art Unit	1646 647										
Examiner Name	RM DEBERR										

examiners C	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
	ite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
pitials* N	o.1 publisher, city and/or country where published	
Y K/)	Ehrenreich H, et. al., Erythropoietin therapy for acute stroke is	,
	both safe and beneficial. Mol Med. 2002;8:495-505.	
	Gorio A, et. al., Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.	
	Hernandez TD, et al., Seizures and recovery from experimental brain damage Exp Neurol. 1988:102:318-324	
	Junk AK, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.	-
	Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493	
	Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampa and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116	
	Nagai A, et al., Erythropoietin and erythropoietin receptors in human conneurons, astrocytes, microglia, and oligodendrocytes grown in culture. Neuropathol Exp Neurol. 2001;60:386-392	
	Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157	e l
	Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci 2002;22:10291-10301.	
	Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582	
	Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276	
	Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.	1
.]	Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803	· [
	Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748	á
	Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651	2
	Digicayflogiu, M. et al. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF kB signaling cascades, Nature 2001 Vol. 412	
12	Juul, Sandra, Erythropoletin and Erythropoletin Receptor In the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1 Koshimura, K. et al, Effects of Erythropoletin on Neuronal Activity, Journal of Neurochemistry, 1999	3

				ـمـد	L J	1	\sim	`		١	. 1		-	1			
Examiner Signature	M	M	YC		19	V			Date Considered	7	7	3	//	\mathcal{T}	(F	7	
						${f au}$			 		7	$\overline{}$	_	7			

*EXAMINER: Initial if reference considered, whether or not cligation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English tanguage Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 3

o respond to a collection of information (iniess a displays a valio CMB control number.
Confirmation Number	9072
Application Number	10/810,755
Filing Date	03/26/2004
First Named Inventor	Michael J. Renzl
Group Art Unit	1846 1647
Examiner Name	RM NBUY

		OTHER PRIOR ART - NON PAYENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
10	110.	Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts	
<i>N</i> M 1		during focal stroke and neuroprotective effects of aminoguanidine.	
		Proc Natl Acad Sci U S A. 1995; 92: 3744-3748	
$\stackrel{\cdot}{-}$		Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in	
1 1		Bernaudin, myriam, et al, a potential kole for Erythropoletin in	
- 1		Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood	
		flow and Metabolism, 1999, 19-643-651	
- 1		Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between	
		Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412	
		Juul, Sandra, Erythropoietin and Erythropoletin Receptor in the Developing Human Central	
		Nervous System, Pediatric Research, 1998, Vol. 43 No 1	
		Koshimura, K. et al, Effects of Erythropoietin on Neuronal Activity, Journal of Neurochemistry,	
1 1		1999	
		Masuda, S. et. al. Funcional Erythropoletin Receptor of the Cells with Neural Characteristics,	
1 1		The Journal of Biological Chemistry, 1993, Vol. 268 No 15 pp. 11208-11216	
		Nomina or adoqual Chamistry, 1993, Vol. 209 NO 15 Pt. 11205-11215	
1 1		Namura, S. et al, Intravenoous administration of MEK inhibitor U0126 affords brain protection	
1 1		against forebrain ischemia and focal cerebral ischemia, PNAS 2001, vol. 98 no. 20 pp. 11569-	
		11574	
- 1	•	Murray, B. et al, Inhibition of the p44/42 MAP Kinase pathway protects hippocampal neurons	-
		in a cell-culture model of seizure activity, Proc. Natl Acad. Sci, 1998, Vol. 95 pp. 11974-11980	
		Alafaci, C. et al. Effects of recombinant human erythropoletin on cerebral ischemia following	
- 1 1		experimental suarachnoid hemorrhage, European Journal of Pharmacology, 406 (2000) 219-	
- 1 1		225	
		Alessandrini, A. et al, MEK1 protein kinase inhibition protects against damage resulting from	
1 1		focal cerebral ischemia, PNAS 1999 Vol 98 No 22 pp. 12866-12869	
		Sinor, A., Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and	
		AMPA toxicity, Neuroscience Letters 290 (2000) 213-215	
1 1		Sakanaka, Masahiro, In vivo evidence that erythropoletin protects neurons from ischemic	
		damage, Proc Natl Acad Sci, 1998 Vol. 95 pp. 4635-4640	
(Ribatt, D. et al, Human Erythropoletin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo, Blood, 1999 Vol 98 No 8 pp	
1 1		2627-2636	
10		.Westenfelder, C. et al, Human, rat, and mouse kidney cells express functional	
M > 1		anthonoich contain Video lateration 1000 kg/rs 1000 k	
		erythropoietin receptors, Kidney International, 1999 Vol 55, pp. 808-820	
		•	
1			
			
	-		
i			
I			
$\overline{}$			
		<u> </u>	

				Ω			_	1.	-7	1		
Examiner Signature	VX.	71	NULA	7	Date Considered		7	7 र	0	7	07	
				$\overline{}$			77		-	, 		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, OC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number, 2 Applicant is to place a check mark here if English tanguage Translation is attached.